<table>
    <tr>
        <th>Template</th>
        <th>Technical</th>
    </tr>
    <tr>
        <td>Original Protocol Indicator</td>
        <td>Country Identifier or Region Identifier or Site Identifier</td>
    </tr>
    <tr>
        <td>Country Identifier</td>
        <td>Approval Date or State location where Information can be found</td>
    </tr>
    <tr>
        <td>Region Identifier</td>
        <td>sponsor signature block name and title of sponsor signatory and signature date or This protocol was approved
            via describe method</td>
    </tr>
    <tr>
        <td>Site Identifier</td>
        <td>Describe Method</td>
    </tr>
    <tr>
        <td>State location where information can be found</td>
        <td>Amendment Details</td>
    </tr>
    <tr>
        <td>describe method</td>
        <td>The table below describes the current amendment</td>
    </tr>
    <tr>
        <td>Primary Reason for Amendment</td>
        <td>Approximately enrolled GloballyLocallyby Cohort</td>
    </tr>
    <tr>
        <td>Secondary Reason for Amendment</td>
        <td>Number or</td>
    </tr>
    <tr>
        <td>Population type</td>
        <td>Other description</td>
    </tr>
    <tr>
        <td>Intervention model</td>
        <td>If yes briefly explain</td>
    </tr>
    <tr>
        <td>Population diagnosis or condition</td>
        <td>Table of Contents</td>
    </tr>
    <tr>
        <td>INN</td>
        <td>NonProprietary Names</td>
    </tr>
    <tr>
        <td>Site distribution</td>
        <td>Intervention Model</td>
    </tr>
    <tr>
        <td>Intervention assignment method</td>
        <td>Population Type</td>
    </tr>
    <tr>
        <td>Master Protocol Indicator</td>
        <td>Nonproprietary name or INN or Enter Not applicable</td>
    </tr>
    <tr>
        <td>DrugDevice Combination Product Indicator</td>
        <td>or INN or</td>
    </tr>
    <tr>
        <td>Adaptive Trial Design Indicator</td>
        <td>Minimum age</td>
    </tr>
    <tr>
        <td>randomly assigned to trial interventionenrolled</td>
        <td>Intervention Assignment Method</td>
    </tr>
    <tr>
        <td>total planned duration of trial intervention</td>
        <td>Site Distribution</td>
    </tr>
    <tr>
        <td>total planned duration of trial intervention unit of time</td>
        <td>randomly assigned to trial intervention enrolled</td>
    </tr>
    <tr>
        <td>total planned duration of trial participation</td>
        <td>Table of Estimand Characteristics including Endpoint at a minimum</td>
    </tr>
    <tr>
        <td>total planned duration of trial participation unit of time</td>
        <td>PopulationLevel Summary</td>
    </tr>
    <tr>
        <td>Populationlevel Summary</td>
        <td>Secondary Objective X</td>
    </tr>
    <tr>
        <td>Rationale for Intervention Model</td>
        <td>If a Secondary Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a
            minimum</td>
    </tr>
    <tr>
        <td>description of the overview of trial interventions or a heading for the optional table below</td>
        <td>Intercurrent Event Strategy</td>
    </tr>
    <tr>
        <td>Select Route of Administration</td>
        <td>If an Exploratory Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a
            minimum</td>
    </tr>
    <tr>
        <td>RegimenTreatment PeriodVaccination Regimen</td>
        <td>Intercurrent Event Strategy</td>
    </tr>
    <tr>
        <td>Select Use</td>
        <td>Rationale for Trial Intervention Model</td>
    </tr>
    <tr>
        <td>Select Sourcing</td>
        <td>Prospective approval of protocol deviations to recruitment and enrollment criteria also known as protocol
            waivers or exemptions is not permitted</td>
    </tr>
    <tr>
        <td>Other Noninvestigational Trial Intervention</td>
        <td>To be eligible to participate in this trial an individual must meet all the following criteria</td>
    </tr>
    <tr>
        <td>Clinical Laboratory Assessments</td>
        <td>Inclusion Criterion</td>
    </tr>
    <tr>
        <td>Definitions of Product Complaints</td>
        <td>An individual who meets any of the following criteria will be excluded from participation in this trial</td>
    </tr>
    <tr>
        <td>Timing for reporting to Sponsor or Designee</td>
        <td>Exclusion Criterion</td>
    </tr>
    <tr>
        <td>Diseaserelated Events or Outcomes not Qualifying as AEs or SAEs</td>
        <td>Description of the overview of trial interventions or a heading for the optional table below</td>
    </tr>
    <tr>
        <td>CountryRegion Identifier</td>
        <td>RegimenTreatment PeriodVaccination regimen</td>
    </tr>
    <tr>
        <td>enter amendment number</td>
        <td>Use</td>
    </tr>
    <tr>
        <td>enter date</td>
        <td>Sourcing</td>
    </tr>
    <tr>
        <td>Globally Locally Cohort</td>
        <td>Additional Text if Needed</td>
    </tr>
    <tr>
        <td>Minimum Age</td>
        <td>Other Noninvestigational Intervention</td>
    </tr>
    <tr>
        <td>Analysis Associated with Exploratory Objectives</td>
        <td>Clinical Safety Laboratory Assessments</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Definition of Product Complaints</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Timing for Reporting to Sponsor or Designee</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Adverse Events of Special Interest or state Not applicable</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Diseaserelated Events or Outcomes Not Qualifying as AEs or SAEs</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Analysis Associated with Exploratory Objectivess</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Prior Protocol Amendments</td>
    </tr>
    <tr>
        <td>None</td>
        <td>or</td>
    </tr>
    <tr>
        <td>None</td>
        <td>amendment number</td>
    </tr>
    <tr>
        <td>None</td>
        <td>Enter Appendix</td>
    </tr>
</table>